

New Drug Development in Korea - Hanmi Case -

1st Japan-Korea Joint Symposium on Medical Products, June 23rd, 2016, Tokyo

Gwan Sun Lee

President & CEO





Company Overview

H H

Hanmi





China Market



Partnership & Alliance



\$7B _ Record-breaking Deals*

28 Pipelines on Track


~700% Market cap. Growth**

11.57 (660,863 (11710)

*Sum of upfront and potential milestones from major deals in 2015 **As of 30 December 2015

Company Structure






*Number of Researchers = Dongtan + Seoul + Paltan + Hanmi FC + Beijing Research Center

Hanmi Way – Evolution & Innovation



Continuously reinventing itself, Hanmi adapted to fast-changing global demand and provided innovative medical solutions









Company Overview







China Market



Partnership & Alliance



"For the 10th year, our research demonstrates that there's no correlation between how much you spend on innovation and how well you perform. You can't just buy your way to the top." – Barry Jaruzelski, Sr. Partner of PWC



R&D Network





Formulation Research Center

- : Paltan, Gyeonggi-do
- Formulation, DDS Research
- R&D Staff: 63 (Ph.D 6, MS. 34)



Beijing Hanmi Research Center

- : Beijing China
- NCE & NBE Drug Discovery
- Equipped with primate facility
- R&D Staff: 160 (Ph.D 14, MS. 88)



Hanmi R&D Center

- : Dongtan, Gyeonggi-do
- NCE & NBE Drug Discovery
- R&D Staff: 147 (Ph.D 27, MS. 94)

Total R&D Staff : 520+





Seoul Research Center (HQ)

- : Songpa-gu, Seoul
- eR&D, Clinical & Regulatory
- R&D Staff: 103 (Ph.D 12, MS. 47)




Hanmi Fine Chem

- : Shihwa, Gyeonggi-do
- Mass Production Research of APIs
- R&D Staff: 50 (Ph.D 3, MS. 39)

R&D Investment



Ranked 1st in Korea for investing in New Drug Development






Open innovation

Leveraging External Sources of Innovation







Global Development Strategy

- Select candidates with best-in-class/first-in-class potential
- Plan global development strategy from the beginning and prioritize the program periodically based on competitive landscape
- Focus the resources on the high priority projects


Maximize the Internal/ External Human Resources

- · Continuous technology innovation through in house staffs
- Recruitment of multinational talents in clinical science, business development, regulatory affairs, and CMC
- Formulation of global advisory board in diabetes and oncology for the consultation of right developmental path



Long-Acting Protein/Peptide Discovery Technology (Fusion of Chemistry to Biologics)

"Monomeric Form and Aglycosylated Fc Enables Longest Duration"



R&D Pipeline



Pre-clinical (8)	> Phase 1 (8)	> Phase 2 (6)	➢ Phase 3 (6)
HM14220* <mark>1</mark>	HM12470	Efpeglenatide	Eflapegrastim
(LAPS Insulin Combo / Diabetes & Obesity)	(LAPS Insulin 115 / Diabetes)	(LAPS Exd4 / Diabetes & Obesity)	(LAPS GCSF / Neutropenia)
Diabetes Program	HM12525A 3	Efpegsomatropin (HM10560A)	HGP1207
	(LAPSGLP/GCG / Diabetes & Obesity)	(LAPS hGH / GHD)	(Pulmonary arterial hypertension)
Obesity Program	HM71224 4	Olmutinib (HM61713**)	HCP1105
	(BTK inhibitor / Auto-Immune disease)	(EGFR mutant selective / NSCLC)	(Complex dyslipidemia)
AML Program	HM95573	Poziotinib 6	HCP1305
	(RAF inhibitor / Solid tumor)	(pan-Her inhibitor / Breast cancer)	(Hypertension & Hypercholesterolemia)
Cancer Immunotherapy Program	Oratecan TM 7	Oraxol ^{TM***} 7	HCP1401
	(oral anticancer drug / Solid tumor)	(oral anticancer drug / Breast cancer)	(Hypertension)
Cancer/Fibrosis Program	KX2-391 7	Luminate [®] 8	HCP1303
	(src/tubulin inhibitor / Solid tumor)	(integrin inhibitor / DME)	(BPH & Erectile dysfunction)
Auto-Immune Program I	HCP1405 (Osteoporosis)		
Auto-Immune Program II	HCP1202 (COPD)		NDA sumitted (1)

HCP1302

IMD/FDC (8) *Ready for IND submission 1. Sanofi **NDA submitted in Korea 2. Spectrum ***Phase 3 in South America 3. Janssen 4. Eli Lilly

New Biologics (8)

NCE (13)

5. Boehringer Ingelheim / Zailab

- 6. Spectrum / Luye
- 7. Athenex

Out-licensed (10)

In-licensed (2)

8. Allegro Ophthalmics







Company Overview

H





China Market



Partnership & Alliance



Fully integrated from R&D, manufacturing to sales and marketing in China

Beijing R&D	Manufacturing Sales & Marketing
Established	Mar. 27th, 1996
Shareholdings	Hanmi Pharm: 73.7%; China Resources Group: 26.3%
Employees	1,428 (as of Dec. 2015)
Total Sales	1,130 Mil. RMB (172 Mil. USD) (as of 2015)
R&D Investment	86.2 Mil. RMB (13.1 Mil. USD) (7.6% of 2015 sales)



NO.1 Pediatric Market Share

No.1 probiotics product 'Mamiai' (for children) No.1 anti-cough and expectorant product 'Yitanjing' (for children)



63 Mil. USD, 2015 (450 Mil. RMB)

Modulator of intestinal flora



Nationwide Sales Network

1000 Sales force 32 **Provinces** +300Cities +9,000**Hospitals 100% Children's Hospital** 90% Large-sized Hospital **100% Medium-sized Hospital** +27,000**Health service** 68% Pharmacy +110,000**Rx Doctors**

Yitanjing 55 Mil. USD, 2015 (360 Mil. RMB)

Expectorant cough medicine





Focus on the innovative new drug discovery & development

160 R&D staff

7.6% Sales to R&D Investment

Animal facility for rodents, beagles, and non-human primates High-tech enterprise certification

NCE	New Biologics	BIO Production
✓ Auto-immune	✓Oncology	✓ LAPScovery product
✓ Oncology	✓ Auto-immune	✓ Local manufacturing
✓ First-in-class or Best-in-class	✓ Next generation antibody	for China market access



Hanmi's China Strategy and Partnership











Company Overview

H





China Market



Partnership & Alliance



Maximize Value to Full Potential	 Extensive development and commercialization capability Strong presence in the market with proven track record of success Portfolio fit with high priority


- Positive interaction during course of discussion
- Openness and willingness to understand each other
- Track record of sustainable partnership

Good Working

Chemistry

Recent Global Partnership





ZCILab. HM61713

3rd generation EGFR TKI Exclusive licensing China including Hong Kong, Macau

Hanmi



- Focus the Resources into Core Research Area

New Chemicals: Oncology & Autoimmune → Lead the world's new research trends

- Efficient R&D through Platform Technology

New Biologics: Rapid generation of candidates through **LAPSCOVERY Platform** Focus the pipelines in Diabetes & Obesity \rightarrow Strong Expertise in Metabolic Disease Area

- Maximize the internal/external Human Resources

Maintain the internal research leadership and recruit the external talents Formulation of Global Scientific Advisory Board & Consultation for Development Path

- Rapid Decision Process


Decision through discussion between scientific leaderships and senior managements

- Pre-determined Internal Consensus for the Right Partner

Extensive strategic analysis for the competing partner groups Strategy for the maximization of deal value through multiple potential partners Execute the deal negotiation process focusing on the partner which can maximize the value of our asset


What's next?







Hanmi Open Innovation Home Page(http://oi.hanmi.co.kr)



"Creating the future together"

Hanmi

Thank you!

5